Pegylated arginine deiminase (ADI-PEG 20)

ADI-PEG 20, also called pegargiminase, is an enzyme therapy from Polaris Pharmaceuticals that starves cancer cells of arginine, an amino acid some tumors cannot make on their own. This specific database entry tracks NCT05813327 [1], a Washington University Phase 1/2 neoadjuvant study (neoadjuvant means the drug is given before surgery to shrink the tumor and make it easier to remove) combining ADI-PEG 20 with ifosfamide chemotherapy and pre-operative radiation in resectable soft tissue sarcoma. That sarcoma trial is a small academic slice of a much larger commercial program. The compound already delivered a positive Phase 3 readout in nonepithelioid pleural mesothelioma (ATOMIC-Meso, published in JAMA Oncology in February 2024) [2], where adding pegargiminase to standard cisplatin and pemetrexed extended median overall survival from 10.7 to 14.3 months (hazard ratio 0.77, p=0.031) and improved median progression-free survival from 5.6 to 7.4 months. Polaris completed a rolling BLA submission on that dataset on June 9, 2025, and the FDA accepted the file for substantive review on August 18, 2025 [7], putting a first potential approval decision in view for late 2025 or 2026 depending on review classification. Polaris is separately enrolling a randomized Phase 3 in hepatocellular carcinoma restricted to patients with elevated blood arginine (NCT05317819) [3]. Polaris is a private company and pegargiminase is its lead asset, the anchor of a multi-decade bet that some tumors have a fatal weakness in amino-acid metabolism that can be exploited from outside the cell.

ADI-PEG 20 is a novel biologic that has not been approved anywhere. Polaris has been developing it for more than 20 years, and the program is now mature. The ATOMIC-Meso Phase 3 in nonepithelioid pleural mesothelioma read out positive in February 2024 [2]. Polaris initiated a rolling BLA submission in November 2023, completed the final module on June 9, 2025, and the FDA accepted the application for substantive review on August 18, 2025 [7]. That review clock is the single most important near-term event for the compound. Polaris has not publicly disclosed the PDUFA (Prescription Drug User Fee Act) action date; a standard 10-month review from August 2025 would land mid-2026, while priority review would be earlier. The absence of a public PDUFA disclosure is itself notable and worth watching. FDA and EMA granted orphan drug designation for pegargiminase in both mesothelioma and hepatocellular carcinoma (orphan drug designation applies to therapies for diseases affecting fewer than 200,000 US patients per year and confers seven years of market exclusivity, tax credits, and user-fee waivers). The compound does not currently hold breakthrough therapy or fast track status for the sarcoma indication captured in this record. The specific Phase 1/2 sarcoma trial NCT05813327 is investigator-sponsored by Washington University in St. Louis and is listed on ClinicalTrials.gov as active but not recruiting, which typically means dosing is complete and follow-up is ongoing. Primary completion date and readout timing are not specified in the fields available for this record. The commercially consequential trials to track sit elsewhere in the Polaris program: the mesothelioma BLA under FDA review, a prior WashU Phase 2 in sarcoma and small cell lung cancer (NCT03449901) that has completed accrual [4], and the ongoing HCC Phase 3 (NCT05317819) [3]. The mesothelioma decision will be the first FDA action on pegargiminase in any indication after two decades of clinical work.

Arginine is one of the 20 amino acids cells use to build proteins. Most human tissues can make their own arginine on demand using an enzyme called ASS1 (short for argininosuccinate synthetase 1). Some tumors silence the ASS1 gene through DNA methylation, essentially switching off the local factory, and become dependent on arginine supplied through the bloodstream. This is what the target biology calls an arginine auxotroph: the tumor cannot manufacture what it needs and must import it. ADI-PEG 20 is a bacterial enzyme, arginine deiminase from Mycoplasma hominis, chemically stitched to polyethylene glycol chains that slow its clearance and dampen immune recognition. Once infused (weekly intramuscular or intravenous dosing across the clinical program), it converts circulating arginine into citrulline. Normal tissues sense the drop and turn on ASS1 to resynthesize arginine locally. ASS1-deficient tumors cannot compensate, run out of arginine, and die. Validation is solid. ASS1 loss is documented in roughly half of pleural mesotheliomas [2], a large fraction of soft tissue sarcomas, subsets of hepatocellular carcinoma [5], some melanomas, and AML. The ATOMIC-Meso Phase 3 was the first randomized proof that depleting a single amino acid from blood can measurably prolong survival in a solid tumor [2]. Where the model gets murky is patient selection: not every ASS1-low tumor responds and some ASS1-expressing tumors do, so the biomarker relationship is real but noisy [5].

NCT05813327 is a single-arm, single-institution Phase 1/2 neoadjuvant study run by Washington University in St. Louis [1]. Patients with resectable soft tissue sarcoma receive ADI-PEG 20 combined with ifosfamide chemotherapy and pre-operative radiation, then proceed to surgical resection. Phase 1 titrates ADI-PEG 20 dosing to establish safety and a recommended Phase 2 dose in combination. Phase 2 typically evaluates pathologic response (a microscopic grading, done by a pathologist on the resected tumor tissue, of what fraction of the original tumor was killed by treatment; the standard threshold in soft tissue sarcoma is >90% necrosis). Exact enrollment target and primary completion date are not specified in the data captured for this record, and ClinicalTrials.gov lists the study as active but not recruiting. Design strengths: neoadjuvant is the cleanest setting to measure a drug's biological effect on a tumor, because the tumor is removed and pathologically graded within weeks of treatment. Combining with ifosfamide is rational because chemotherapy-induced DNA damage should amplify the effect of amino-acid starvation. Radiation adds a third stress on tumor cells already deprived of a nutrient they cannot synthesize. Design weaknesses: single arm, no randomized comparator, small sample size, and no ASS1-status stratification described in the publicly captured details. Pathologic response in soft tissue sarcoma is not a validated regulatory endpoint the way it is in breast cancer, so even a strongly positive readout would not on its own support approval. This is a signal-finding academic study, not a registration trial. The decisive trials for ADI-PEG 20 remain the mesothelioma BLA package [2, 7] and the HCC Phase 3 [3].

Our model estimates a 19% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design; it is held back by smaller-than-typical enrollment for this phase, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk. ASS1 status in sarcoma is heterogeneous within a single tumor, and re-expression of ASS1 during treatment is a documented resistance mechanism, meaning patients can initially respond and then relapse as the tumor turns the arginine factory back on. Without prospective ASS1 stratification, this trial risks diluting any real signal into unselected noise. Safety risk. Bacterial enzymes are inherently immunogenic. Prior ADI-PEG 20 studies have shown patients developing neutralizing anti-drug antibodies within roughly 8-12 weeks, which both erode plasma arginine depletion and can trigger infusion reactions [6]. Pegargiminase has also been associated with pancreatitis, neutropenia, and rare cases of hyperammonemia. The hyperammonemia signal is mechanistically coherent: arginine feeds the urea cycle, the liver's main pathway for excreting nitrogen as urea, so sustained arginine depletion can raise blood ammonia. It is a monitoring flag especially in HCC patients with underlying hepatic dysfunction, and warrants baseline liver function screening in sarcoma patients with heavy prior chemotherapy. Combining pegargiminase with ifosfamide (already nephrotoxic and myelosuppressive) plus radiation raises the tolerability bar substantially, because patients still need to be surgical candidates when the neoadjuvant window closes. Execution risk. NCT05813327 is a single-institution academic trial with small enrollment; delays, dropouts, or protocol amendments carry outsized weight on interpretation. Polaris is a private, cash-constrained company; the mesothelioma review will consume most near-term regulatory and commercial capacity. Polaris has not disclosed a runway figure or recent financing publicly, and the absence of an IPO or major partnership after 20+ years is itself a signal about corporate capacity. Serious investment in sarcoma is contingent on the mesothelioma approval landing and on the HCC Phase 3 [3] reading out positive. Commercial risk. Even a clean sarcoma readout supports at most a follow-on registration study, not direct approval. Neoadjuvant soft tissue sarcoma is a narrow indication (a few thousand US cases per year) with entrenched chemotherapy regimens. Orphan biologic pricing on top of generic ifosfamide will require a demonstrated survival or recurrence-free benefit, not just tumor shrinkage.

Not the trial to watch. This record indexes a small academic neoadjuvant sarcoma study, and the commercially decisive events for ADI-PEG 20 sit elsewhere in the Polaris program. Three signals actually matter. First, the FDA action on the pegargiminase BLA in nonepithelioid pleural mesothelioma. The rolling submission was completed June 9, 2025, and FDA substantive review began August 18, 2025 [7]. Whatever action date the agency has set (Polaris has not disclosed it publicly), the decision is the near-term catalyst. Approval would validate the entire mechanism and pull every other pegargiminase trial, including this sarcoma study, up in strategic priority. The commercial opportunity is narrow but concentrated: US pleural mesothelioma incidence is approximately 3,000 cases per year, of which nonepithelioid histology is roughly 20-30%, so the addressable US population is on the order of 600-900 patients per year. At orphan biologic pricing (analogous programs sit at $150,000-$300,000 per patient per year of treatment), peak US revenue could plausibly reach $100-200M annually if uptake is deep in the eligible histology. Modest by big-pharma standards, meaningful for a private single-asset company. Second, the HCC Phase 3 NCT05317819 [3]. That trial is randomized, placebo-controlled, and restricted to patients with elevated baseline blood arginine, a biomarker-selected design that should produce a cleaner efficacy signal than the single-arm HCC work of the last decade [5]. HCC is a much larger market than mesothelioma and is the more consequential commercial readout. Third, competitive positioning. The only other arginine-depleting enzyme in oncology development is BCT-100 (pegylated recombinant human arginase I), which uses a different enzyme (arginase produces ornithine and urea, deiminase produces citrulline), has a different immunogenicity profile because it is a humanized protein, and is only in Phase 1/2 development in adult and pediatric solid tumors [8]. BCT-100 has no active Phase 3 in any indication that overlaps with the Polaris program, so pegargiminase's first-in-class moat in oncology is durable through at least 2027-2028 on current visibility. Fourth, Polaris's corporate status. The company is private and has carried this compound for more than two decades with no public disclosure of runway or partnership discussions. A mesothelioma approval would plausibly trigger an IPO, a partnership, or an acquisition. Watch for financing announcements paired with regulatory news. Check back after the FDA action on the mesothelioma BLA, or when the HCC Phase 3 hits an interim analysis. The sarcoma slice is worth logging but not worth trading on.